Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 366 entries
Sorted by: Best Match Show Resources per page
Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis [Erratum].

Drug design, development and therapy

Yin Q, Li J, Xia Y, Zhang R.
PMID: 26604692
Drug Des Devel Ther. 2015 Nov 06;9:5947. doi: 10.2147/DDDT.S98298. eCollection 2015.

No abstract available.

Cite
Yin Q, Li J, Xia Y, et al. Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis [Erratum]. Drug Des Devel Ther. 2015;9:5947doi: 10.2147/DDDT.S98298.
Yin, Q., Li, J., Xia, Y., & Zhang, R. (2015). Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis [Erratum]. Drug design, development and therapy, 95947. https://doi.org/10.2147/DDDT.S98298
Yin, Q, et al. "Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis [Erratum]." Drug design, development and therapy vol. 9 (2015): 5947. doi: https://doi.org/10.2147/DDDT.S98298
Yin Q, Li J, Xia Y, Zhang R. Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis [Erratum]. Drug Des Devel Ther. 2015 Nov 06;9:5947. doi: 10.2147/DDDT.S98298. eCollection 2015. PMID: 26604692; PMCID: PMC4642802.
Copy Download .nbib Format: NLM
Erratum: Itraconazole solid dispersion prepared by a supercritical fluid technique: preparation, in vitro characterization, and bioavailability in beagle dogs [Corrigendum].

Drug design, development and therapy

[No authors listed]
PMID: 26273197
Drug Des Devel Ther. 2015 Aug 07;9:4387. doi: 10.2147/DDDT.S91738. eCollection 2015.

No abstract available.

Cite
Erratum: Itraconazole solid dispersion prepared by a supercritical fluid technique: preparation, in vitro characterization, and bioavailability in beagle dogs [Corrigendum]. Drug Des Devel Ther. 2015;9:4387doi: 10.2147/DDDT.S91738.
(2015). Erratum: Itraconazole solid dispersion prepared by a supercritical fluid technique: preparation, in vitro characterization, and bioavailability in beagle dogs [Corrigendum]. Drug design, development and therapy, 94387. https://doi.org/10.2147/DDDT.S91738
"Erratum: Itraconazole solid dispersion prepared by a supercritical fluid technique: preparation, in vitro characterization, and bioavailability in beagle dogs [Corrigendum]." Drug design, development and therapy vol. 9 (2015): 4387. doi: https://doi.org/10.2147/DDDT.S91738
Erratum: Itraconazole solid dispersion prepared by a supercritical fluid technique: preparation, in vitro characterization, and bioavailability in beagle dogs [Corrigendum]. Drug Des Devel Ther. 2015 Aug 07;9:4387. doi: 10.2147/DDDT.S91738. eCollection 2015. PMID: 26273197; PMCID: PMC4532213.
Copy Download .nbib Format: NLM
A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck.

Drug design, development and therapy

MacDonald GC, Rasamoelisolo M, Entwistle J, Cizeau J, Bosc D, Cuthbert W, Kowalski M, Spearman M, Glover N.
PMID: 19920898
Drug Des Devel Ther. 2009 Feb 06;2:105-14. doi: 10.2147/dddt.s3442.

VB4-845 is a scFv-Pseudomonas exotoxin A fusion construct that targets epithelial cell adhesion molecule (EpCAM). A phase I trial was conducted to determine the maximum tolerated dose (MTD) of VB4-845 when administered as weekly intratumoral (IT) injections to patients...

Cite
MacDonald GC, Rasamoelisolo M, Entwistle J, et al. A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck. Drug Des Devel Ther. 2009;2:105-14doi: 10.2147/dddt.s3442.
MacDonald, G. C., Rasamoelisolo, M., Entwistle, J., Cizeau, J., Bosc, D., Cuthbert, W., Kowalski, M., Spearman, M., & Glover, N. (2009). A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck. Drug design, development and therapy, 2105-14. https://doi.org/10.2147/dddt.s3442
MacDonald, Glen C, et al. "A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck." Drug design, development and therapy vol. 2 (2009): 105-14. doi: https://doi.org/10.2147/dddt.s3442
MacDonald GC, Rasamoelisolo M, Entwistle J, Cizeau J, Bosc D, Cuthbert W, Kowalski M, Spearman M, Glover N. A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck. Drug Des Devel Ther. 2009 Feb 06;2:105-14. doi: 10.2147/dddt.s3442. PMID: 19920898; PMCID: PMC2761172.
Copy Download .nbib Format: NLM
Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China.

Drug design, development and therapy

Ma G, Shimada H, Hiroshima K, Tada Y, Suzuki N, Tagawa M.
PMID: 19920899
Drug Des Devel Ther. 2009 Feb 06;2:115-22. doi: 10.2147/dddt.s3535.

Loss of p53 function compromises genetic homeostasis, which induces deregulated DNA replication, damages DNA, and subsequently results in increased resistance to anticancer agents. Pharmacological approaches using recombinant adenoviruses (Ad) have been developed to restore the p53 functions. Another approach...

Cite
Ma G, Shimada H, Hiroshima K, et al. Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China. Drug Des Devel Ther. 2009;2:115-22doi: 10.2147/dddt.s3535.
Ma, G., Shimada, H., Hiroshima, K., Tada, Y., Suzuki, N., & Tagawa, M. (2009). Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China. Drug design, development and therapy, 2115-22. https://doi.org/10.2147/dddt.s3535
Ma, Guangyu, et al. "Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China." Drug design, development and therapy vol. 2 (2009): 115-22. doi: https://doi.org/10.2147/dddt.s3535
Ma G, Shimada H, Hiroshima K, Tada Y, Suzuki N, Tagawa M. Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China. Drug Des Devel Ther. 2009 Feb 06;2:115-22. doi: 10.2147/dddt.s3535. PMID: 19920899; PMCID: PMC2761194.
Copy Download .nbib Format: NLM
Submucosal injection solution for gastrointestinal tract endoscopic mucosal resection and endoscopic submucosal dissection.

Drug design, development and therapy

Uraoka T, Saito Y, Yamamoto K, Fujii T.
PMID: 19920900
Drug Des Devel Ther. 2009 Feb 06;2:131-8. doi: 10.2147/dddt.s3219.

Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) have provided new alternatives for minimally invasive treatment of gastrointestinal adenomas and early-stage cancers that involve a minimum risk of lymph-node metastasis. The use of submucosal injections is essential to...

Cite
Uraoka T, Saito Y, Yamamoto K, et al. Submucosal injection solution for gastrointestinal tract endoscopic mucosal resection and endoscopic submucosal dissection. Drug Des Devel Ther. 2009;2:131-8doi: 10.2147/dddt.s3219.
Uraoka, T., Saito, Y., Yamamoto, K., & Fujii, T. (2009). Submucosal injection solution for gastrointestinal tract endoscopic mucosal resection and endoscopic submucosal dissection. Drug design, development and therapy, 2131-8. https://doi.org/10.2147/dddt.s3219
Uraoka, Toshio, et al. "Submucosal injection solution for gastrointestinal tract endoscopic mucosal resection and endoscopic submucosal dissection." Drug design, development and therapy vol. 2 (2009): 131-8. doi: https://doi.org/10.2147/dddt.s3219
Uraoka T, Saito Y, Yamamoto K, Fujii T. Submucosal injection solution for gastrointestinal tract endoscopic mucosal resection and endoscopic submucosal dissection. Drug Des Devel Ther. 2009 Feb 06;2:131-8. doi: 10.2147/dddt.s3219. PMID: 19920900; PMCID: PMC2761197.
Copy Download .nbib Format: NLM
Maraviroc in the treatment of HIV infection.

Drug design, development and therapy

Ray N.
PMID: 19920903
Drug Des Devel Ther. 2009 Feb 06;2:151-61. doi: 10.2147/dddt.s3474.

While a successful HIV vaccine will likely take several more years to become a reality, many anti-retroviral (ARV) drugs are currently available to treat HIV infection, and their efficacious use has improved the quality of life and life expectancy...

Cite
Ray N. Maraviroc in the treatment of HIV infection. Drug Des Devel Ther. 2009;2:151-61doi: 10.2147/dddt.s3474.
Ray, N. (2009). Maraviroc in the treatment of HIV infection. Drug design, development and therapy, 2151-61. https://doi.org/10.2147/dddt.s3474
Ray, Neelanjana. "Maraviroc in the treatment of HIV infection." Drug design, development and therapy vol. 2 (2009): 151-61. doi: https://doi.org/10.2147/dddt.s3474
Ray N. Maraviroc in the treatment of HIV infection. Drug Des Devel Ther. 2009 Feb 06;2:151-61. doi: 10.2147/dddt.s3474. PMID: 19920903; PMCID: PMC2761192.
Copy Download .nbib Format: NLM
Antidiabetic Bis-Maltolato-OxoVanadium(IV): conversion of inactive trans- to bioactive cis-BMOV for possible binding to target PTP-1B.

Drug design, development and therapy

Scior T, Mack HG, García JA, Koch W.
PMID: 19920909
Drug Des Devel Ther. 2009 Feb 06;2:221-31.

The postulated transition of Bis-Maltolato-OxoVanadium(IV) (BMOV) from its inactive trans- into its cis-aquo-BMOV isomeric form in solution was simulated by means of computational molecular modeling. The rotational barrier was calculated with DFT - B3LYP under a stepwise optimization protocol...

Cite
Scior T, Mack HG, García JA, et al. Antidiabetic Bis-Maltolato-OxoVanadium(IV): conversion of inactive trans- to bioactive cis-BMOV for possible binding to target PTP-1B. Drug Des Devel Ther. 2009;2:221-31
Scior, T., Mack, H. G., García, J. A., & Koch, W. (2009). Antidiabetic Bis-Maltolato-OxoVanadium(IV): conversion of inactive trans- to bioactive cis-BMOV for possible binding to target PTP-1B. Drug design, development and therapy, 2221-31.
Scior, Thomas, et al. "Antidiabetic Bis-Maltolato-OxoVanadium(IV): conversion of inactive trans- to bioactive cis-BMOV for possible binding to target PTP-1B." Drug design, development and therapy vol. 2 (2009): 221-31.
Scior T, Mack HG, García JA, Koch W. Antidiabetic Bis-Maltolato-OxoVanadium(IV): conversion of inactive trans- to bioactive cis-BMOV for possible binding to target PTP-1B. Drug Des Devel Ther. 2009 Feb 06;2:221-31. PMID: 19920909; PMCID: PMC2761195.
Copy Download .nbib Format: NLM
Drug design with Cdc7 kinase: a potential novel cancer therapy target.

Drug design, development and therapy

Sawa M, Masai H.
PMID: 19920912
Drug Des Devel Ther. 2009 Feb 06;2:255-64. doi: 10.2147/dddt.s4303.

Identification of novel molecular targets is critical in development of new and efficient cancer therapies. Kinases are one of the most common drug targets with a potential for cancer therapy. Cell cycle progression is regulated by a number of...

Cite
Sawa M, Masai H. Drug design with Cdc7 kinase: a potential novel cancer therapy target. Drug Des Devel Ther. 2009;2:255-64doi: 10.2147/dddt.s4303.
Sawa, M., & Masai, H. (2009). Drug design with Cdc7 kinase: a potential novel cancer therapy target. Drug design, development and therapy, 2255-64. https://doi.org/10.2147/dddt.s4303
Sawa, Masaaki, and Masai, Hisao. "Drug design with Cdc7 kinase: a potential novel cancer therapy target." Drug design, development and therapy vol. 2 (2009): 255-64. doi: https://doi.org/10.2147/dddt.s4303
Sawa M, Masai H. Drug design with Cdc7 kinase: a potential novel cancer therapy target. Drug Des Devel Ther. 2009 Feb 06;2:255-64. doi: 10.2147/dddt.s4303. PMID: 19920912; PMCID: PMC2761190.
Copy Download .nbib Format: NLM
The evolving role of alemtuzumab (Campath-1H) in renal transplantation.

Drug design, development and therapy

Pham PT, Lipshutz GS, Pham PT, Kawahji J, Singer JS, Pham PC.
PMID: 19920920
Drug Des Devel Ther. 2009 Sep 21;3:41-9.

The introduction of new immunosuppressive agents into clinical transplantation in the 1990s has resulted in excellent short-term graft survival. Nonetheless, extended long-term graft outcomes have not been achieved due in part to the nephrotoxic effects of calcineurin inhibitors (CNIs)...

Cite
Pham PT, Lipshutz GS, Pham PT, et al. The evolving role of alemtuzumab (Campath-1H) in renal transplantation. Drug Des Devel Ther. 2009;3:41-9
Pham, P. T., Lipshutz, G. S., Pham, P. T., Kawahji, J., Singer, J. S., & Pham, P. C. (2009). The evolving role of alemtuzumab (Campath-1H) in renal transplantation. Drug design, development and therapy, 341-9.
Pham, Phuong-Thu T, et al. "The evolving role of alemtuzumab (Campath-1H) in renal transplantation." Drug design, development and therapy vol. 3 (2009): 41-9.
Pham PT, Lipshutz GS, Pham PT, Kawahji J, Singer JS, Pham PC. The evolving role of alemtuzumab (Campath-1H) in renal transplantation. Drug Des Devel Ther. 2009 Sep 21;3:41-9. PMID: 19920920; PMCID: PMC2769238.
Copy Download .nbib Format: NLM
Alitretinoin--its use in intractable hand eczema and other potential indications.

Drug design, development and therapy

Petersen B, Jemec GB.
PMID: 19920921
Drug Des Devel Ther. 2009 Sep 21;3:51-7. doi: 10.2147/dddt.s3178.

Chronic hand eczema is a significant cause of morbidity. A number of treatments are traditionally used, and often useful, but in spite of this a sizeable group of patients develop chronic recalcitrant hand eczema. Retinoids are known to influence...

Cite
Petersen B, Jemec GB. Alitretinoin--its use in intractable hand eczema and other potential indications. Drug Des Devel Ther. 2009;3:51-7doi: 10.2147/dddt.s3178.
Petersen, B., & Jemec, G. B. (2009). Alitretinoin--its use in intractable hand eczema and other potential indications. Drug design, development and therapy, 351-7. https://doi.org/10.2147/dddt.s3178
Petersen, Bibi, and Jemec, Gregor B E. "Alitretinoin--its use in intractable hand eczema and other potential indications." Drug design, development and therapy vol. 3 (2009): 51-7. doi: https://doi.org/10.2147/dddt.s3178
Petersen B, Jemec GB. Alitretinoin--its use in intractable hand eczema and other potential indications. Drug Des Devel Ther. 2009 Sep 21;3:51-7. doi: 10.2147/dddt.s3178. PMID: 19920921; PMCID: PMC2769244.
Copy Download .nbib Format: NLM
Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib.

Drug design, development and therapy

Swords R, Mahalingam D, Padmanabhan S, Carew J, Giles F.
PMID: 19920925
Drug Des Devel Ther. 2009 Sep 21;3:89-101. doi: 10.2147/dddt.s3069.

Chronic myeloid leukemia (CML) is the consequence of a single balanced translocation that produces the BCR-ABL fusion oncogene which is detectable in over 90% of patients at presentation. The BCR-ABL inhibitor imatinib mesylate (IM) has improved survival in all...

Cite
Swords R, Mahalingam D, Padmanabhan S, et al. Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Des Devel Ther. 2009;3:89-101doi: 10.2147/dddt.s3069.
Swords, R., Mahalingam, D., Padmanabhan, S., Carew, J., & Giles, F. (2009). Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug design, development and therapy, 389-101. https://doi.org/10.2147/dddt.s3069
Swords, Ronan, et al. "Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib." Drug design, development and therapy vol. 3 (2009): 89-101. doi: https://doi.org/10.2147/dddt.s3069
Swords R, Mahalingam D, Padmanabhan S, Carew J, Giles F. Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Des Devel Ther. 2009 Sep 21;3:89-101. doi: 10.2147/dddt.s3069. PMID: 19920925; PMCID: PMC2769239.
Copy Download .nbib Format: NLM
Changes in CD4+ T-cells and HIV RNA resulting from combination of anti-TB therapy with Dzherelo in TB/HIV dually infected patients.

Drug design, development and therapy

Nikolaeva LG, Maystat TV, Masyuk LA, Pylypchuk VS, Volyanskii YL, Kutsyna GA.
PMID: 19920896
Drug Des Devel Ther. 2009 Feb 06;2:87-93.

The open-label, phase II clinical trial of antituberculosis therapy (ATT) with or without oral immunomodulator Dzherelo (Immunoxel) was conducted in TB/HIV coinfected, antiretroviral therapy naïve patients to evaluate the effect on CD4 T-lymphocyte counts and viral load. The arm...

Cite
Nikolaeva LG, Maystat TV, Masyuk LA, et al. Changes in CD4+ T-cells and HIV RNA resulting from combination of anti-TB therapy with Dzherelo in TB/HIV dually infected patients. Drug Des Devel Ther. 2009;2:87-93
Nikolaeva, L. G., Maystat, T. V., Masyuk, L. A., Pylypchuk, V. S., Volyanskii, Y. L., & Kutsyna, G. A. (2009). Changes in CD4+ T-cells and HIV RNA resulting from combination of anti-TB therapy with Dzherelo in TB/HIV dually infected patients. Drug design, development and therapy, 287-93.
Nikolaeva, Lyudmila G, et al. "Changes in CD4+ T-cells and HIV RNA resulting from combination of anti-TB therapy with Dzherelo in TB/HIV dually infected patients." Drug design, development and therapy vol. 2 (2009): 87-93.
Nikolaeva LG, Maystat TV, Masyuk LA, Pylypchuk VS, Volyanskii YL, Kutsyna GA. Changes in CD4+ T-cells and HIV RNA resulting from combination of anti-TB therapy with Dzherelo in TB/HIV dually infected patients. Drug Des Devel Ther. 2009 Feb 06;2:87-93. PMID: 19920896; PMCID: PMC2761183.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 366 entries